Often when a patient walks into a provider's office, he or she might not have any idea about the total cost of the visit-except what the copay might be.
Often when a patient walks into a provider's office, he or she might not have any idea about the total cost of the visit-except what the copay might be.
"In today's world there is a lot of confusion related to consumers understanding their obligation, in that they do not pay for their out-of-pocket costs in a consistent, timely or an efficient manner," says Bill Fandrich, HealthePass Product Executive, for Bloomfield, Conn.-based CIGNA Healthcare. He projects that patients' payments to providers will more than double in the next five years. "The healthcare payment process still operates under the traditional managed-care model, which is a copay patient obligation model that does not effectively address deductible and co-insurance payment obligation," he adds.
To fulfill that need, CIGNA plans to launch its HealthePass solution in 2007 with some of the largest hospital systems and physician groups in the United States. At its core, HealthePass consists of a robust, comprehensive cost calculator that will supply accurate, personalized estimates of patient liability and is intended to be an easily adopted tool for providers that will clearly set financial expectations, shorten providers' revenue cycles and significantly reduce the potential for patient bad debt.
PROVIDER PERSPECTIVE
HealthePass is the product of a thorough reassessment of the healthcare marketplace by CIGNA. While many in the industry might have explored real-time claims adjudication and debit cards, CIGNA also sought input from providers, physician groups, hospitals, employers and others to see the industry from a provider's perspective, according to Fandrich.
"We took a step back and did several months of detailed market analysis, including hundreds of hours of interviews with providers," Fandrich says. "As a byproduct of that, we saw the need to introduce a different kind of solution, one that could work across the various provider business models. We needed to provide a solution that could cross products-PPO plans, consumer-directed plans and other plans with a wide variety of benefit options. We needed to provide a very simple way for both the consumer and provider to understand the patient's financial obligation."
Significant among its multiple functions, HealthePass ensures there is a shared understanding of the patient obligation during the healthcare delivery cycle-before, during or after treatment. Whereas most cost calculators today use the "charge" information to make non-specific cost estimates, HealthePass's calculator generates an estimate based on the specific treatment, provider contract, and a real-time snapshot of the patient's covered benefits.
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Mental Health Comorbidities Affect Uptravi Prescribing for PAH
October 23rd 2024New real-world data suggest that physicians are cautious about prescribing the prostacyclin-receptor agonist Uptravi (selexipag) to pulmonary arterial hypertension (PAH) patients with mental health conditions when evidence suggests that it is best to take a proactive approach to treating PAH.
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
High-Dose Eylea Shows Unique Properties in nAMD and DME | AAO 2024
October 22nd 2024A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks to as long as 20 weeks for neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
Read More